- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06326216
Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the levels of prostate cancer-derived extracellular vesicles pre- and post-radical prostatectomy.
II. Determine the correlation between levels of prostate cancer-derived extracellular vesicles and PSA.
OUTLINE: This is an observational study. Participants are assigned to 1 of 2 cohorts.
COHORT I: Prostate cancer patients undergo blood and urine sample collection on study. Patients' medical records are also reviewed.
COHORT II: Female urology clinic patients and female volunteers undergo blood and urine sample collection on study.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Principal Investigator:
- Eugene D. Kwon, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
* PROSTATE CANCER PATIENTS:
- Age 18+
- Able to give informed consent
- Patients with prostate cancer
Patients treated with primary prostatectomy
- The focus will be on high-risk patients with at least one of either criterion:
- PSA >= 20 ng/ml
- AND/OR Gleason >= 8
- AND/OR clinical stage >= T3
* FEMALE CONTROL PATIENTS:
- Age 18+
- Able to give informed consent
Exclusion Criteria:
* PROSTATE CANCER PATIENTS:
- Unable or unwilling to provide informed consent
- Metastatic prostate cancer - defined evidence of metastatic disease on pre-procedural testing
* FEMALE CONTROL PATIENTS:
- Unable or unwilling to provide informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (Cohort I)
Prostate cancer patients undergo blood and urine sample collection on study.
Patients' medical records are also reviewed.
|
Non-interventional study
|
Observational (Cohort II)
Female urology clinic patients and female volunteers undergo blood and urine sample collection on study.
|
Non-interventional study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of prostate cancer-derived extracellular vesicles (EVs) - radical prostatectomy
Time Frame: Pre-surgery; within two weeks after surgery; 6 weeks to 7 months after surgery (likely collected during routine visits); annual blood collection (optional)
|
Levels of prostate cancer-derived EVs will be assessed using blood and urine samples
|
Pre-surgery; within two weeks after surgery; 6 weeks to 7 months after surgery (likely collected during routine visits); annual blood collection (optional)
|
Levels of prostate cancer-derived extracellular vesicles (EVs) - negative controls
Time Frame: Baseline
|
Levels of prostate cancer-derived EVs will be assess using blood and urine samples
|
Baseline
|
Correlation between prostate specific antigen (PSA) levels and prostate cancer-derived EVs
Time Frame: Baseline
|
PSA levels and EVs will be determined from blood and urine samples and will be assessed by correlation analysis.
|
Baseline
|
Prostate cancer-derived EV levels
Time Frame: Baseline
|
Prostate cancer-derived EV levels will be determined from blood and urine samples and will be assessed by comparative analysis between prostate cancer patients and female patients (negative controls).
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eugene D. Kwon, M.D., Mayo Clinic in Rochester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-011292 (Other Identifier: Mayo Clinic Institutional Review Board)
- NCI-2023-05221 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Carcinoma
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate AdenocarcinomaUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)UnknownCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate CarcinomaUnited States
-
University of WashingtonJanssen Research & Development, LLCTerminatedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Double-Negative Prostate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the BoneUnited States
-
University of UtahCompletedMetastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
-
Jonsson Comprehensive Cancer CenterCompletedBiochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | PSA Level Greater Than FiftyUnited States
-
Emory UniversityCompletedCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7United States
Clinical Trials on Non-Interventional Study
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
Mayo ClinicNational Cancer Institute (NCI)Recruiting
-
Jonsson Comprehensive Cancer CenterRecruitingEarly Stage Breast CarcinomaUnited States
-
Algalarrondo VincentBichat Hospital; BioquantisRecruitingTransthyretin Cardiac Amyloidosis | Transthyretin Amyloid Cardiomyopathy | Amyloid CardiomyopathyFrance
-
Mayo ClinicRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingPancreatic CarcinomaUnited States
-
Mayo ClinicRecruitingBreast Carcinoma | Recurrent Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
Mayo ClinicNot yet recruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
Mayo ClinicRecruitingOropharyngeal Human Papillomavirus-Positive Squamous Cell CarcinomaUnited States
-
Mayo ClinicRecruitingBreast Cancer | Breast Carcinoma | Breast Cancer FemaleUnited States